You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
VRE SCREEN, PCR |
||
Geisinger Epic Procedure Code: LAB3268
Geisinger Epic ID: 43049
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Rectal swab (FDA approved) or perinanal swab | |
Preferred collection container: |
||
Alternate Collection Container: |
Copan Venturi Transystem Liquid Stuart single or double swab
Cepheid sample collection device
BBL CultureSwab Liquid Stuarts single or double swab
|
|
Special notes: |
See Microbiology Collection Appendix for collection instructions. Check expiration date on transport device before use. | |
| SPECIMEN PROCESSING |
||
Transport temperature: |
Room temperature (2-30°C is acceptable) | |
Specimen stability: |
All swab types: 2-8°C for 5 days. Room temperature (15-25°C) = 24 hours. | |
Rejection criteria: |
Improperly labeled/identified specimens. Specimens which exceed stability limits. Expired collection device/swab. Collection of specimen with non-approved swabs. Improper specimen type. | |
TEST DETAILS |
||
Reference interval: |
Negative. No vanA gene detected by PCR (Amplified Probe) | |
Critical values/courtesy alerts: |
Positive. vanA gene detected by PCR (Amplified Probe), Vancomycin Resistant Enterococcus | |
Additional information: |
See vanA (VRE) FAQ Sheet | |
CPT code(s): |
87500 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
The direct detection of colonization of Vancomycin Resistant Enterococci - VRE (vanA gene) to aid in the prevention and control of VRE infections in healthcare settings. | |
Methodology: |
Real-time Polymerase Chain Reaction (PCR) |
|
Synonyms: |
VRE, Enterococci, Enterococcus, rectal, perianal, culture, screen, Vancomycin resistance, VRE, E. faecium, E. faecalis VREP
|
|
Clinical significance: |
Colonization with vanA (VRE) has been shown to be a significatant risk factor for transmission of VRE to other hospitalized or institutionalized patients. | |
Doctoral Director(s:) |
Donna Wolk PhD, D(ABMM), Raquel Martinez, PhD, D(ABMM) | |
| Review Date: | 12/31/2022 | |